
臨床神經研究團隊 | |
姓名 | 王 培寧 |
電子郵件 | pnwang@vghtpe.gov.tw |
POSITION TITLE/AFFILIATIONS | Professor/ Department of Neurology, School of Medicine, National Yang-Ming Chiao Tung University Attending Physicision/ Department of Neurology, Taipei Veterans General Hospital |
EDUCATION/TRAINING | 1983-1990 MedicineMD, National Yang-Ming University, Taipei, Taiwan 1992-1997 Resident in Neurology, Department of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan 2003-2004 Behavior Neurology FellowshipMemory and Aging Center, University of California, San Francisco, USA |
Service | 陽明大學醫學系畢業,曾任美國加州大學舊金山分校(UCSF) 記憶和老化研究中心臨床研究員, 現任陽明大學神經科教授,台北榮民總醫院失智症治療及研究中心主任,Journal of Alzheimer’s disease 、Journal of Clinical Gerontology and Geriatrics、Plos one編輯,台灣臨床失智症學會理事,台灣失智症協會理事,台灣神經學會行為神經學組,台灣老年學暨老年醫學會學術委員會委員。 臨床和學術專長為失智症、年輕型失智症,神經退化性疾病,老年神經學,神經影像學和行為神經學。 |
職稱 | 台北榮民總醫院 一般神經科 主治醫師 |
研究專長 | The biomarkers of dementia, especially Alzheimer disease (AD) in Taiwan |
研究概況 | My research is focus on investigating the biomarkers of dementia, especially Alzheimer disease (AD) in Taiwan. In the earlier years, we made efforts on establish the validity of the Chinese-version neuropsychological tests to make a accurate early diagnosis of mild AD and mild cognitive impairment (MCI). We published the presentations of verbal memory, executive function, language functions and daily functions in MCI and mild AD. Recently, we cooperated with experts in genetics, pharmacology, biochemistry, and neuroimaging for extending our research to the bio-molecular and neuroimaging aspects of dementia. As PI or co-Investigator on several national and hospital funded grants, I laid the groundwork for the proposed research by investigating biomarkers for early diagnosis of Alzheimer’s disease and prediction the progress from aging to mild cognitive impairment and dementia. We found the rate of hippocampal atrophy was note only higher in progressive MCI, but also in stable MCI. Longitudinally evaluating hippocampal volume may be more sensitive than neuropsychological tests to detect the progression of MCI. Last year, we published the special patterns of axonal degeneration and myelin degradation in different brain regions in MCI and mild AD. In the next few years, our research focus will be placed on inspecting the trajectory of different biomarkers from preclinical AD, MCI due to AD, to dementia due to AD. |